Latest Articles
Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Cancer - Yahoo Finance
Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Cancer Yahoo Finance
Published: Feb. 27, 2026, 4:47 p.m.
ACRV: ACR-368 delivers strong efficacy and safety in serous endometrial cancer, advancing toward approval - TradingView
ACRV: ACR-368 delivers strong efficacy and safety in serous endometrial cancer, advancing toward approval TradingView
Published: Feb. 27, 2026, 3:34 p.m.
ACRV: ACR-368 shows high efficacy and safety in serous endometrial cancer, supporting global expansion - TradingView
ACRV: ACR-368 shows high efficacy and safety in serous endometrial cancer, supporting global expansion TradingView
Published: Feb. 27, 2026, 2:50 p.m.
Acrivon (NASDAQ: ACRV) shows ACR-368 activity in endometrial cancer - Stock Titan
Acrivon (NASDAQ: ACRV) shows ACR-368 activity in endometrial cancer Stock Titan
Published: Feb. 27, 2026, 2 p.m.
Endometrial cancer, Bellet (Acto): "Ensure access to new therapies nationwide." - lamilano.it
Endometrial cancer, Bellet (Acto): "Ensure access to new therapies nationwide." lamilano.it
Published: Feb. 23, 2026, 5:18 p.m.
Endometrial cancer, Campagnoli (GSK): "Immunotherapy increases overall survival." - lamilano.it
Endometrial cancer, Campagnoli (GSK): "Immunotherapy increases overall survival." lamilano.it
Published: Feb. 23, 2026, 5:15 p.m.
Endometrial cancer, Lorusso (Humanitas): "Immunotherapy is effective even in pMMR forms." - lamilano.it
Endometrial cancer, Lorusso (Humanitas): "Immunotherapy is effective even in pMMR forms." lamilano.it
Published: Feb. 23, 2026, 5:12 p.m.
PCOS Long-Term Health Risks: From Infertility And Type 2 Diabetes To Heart Disease And Endometrial Cancer - TheHealthSite
PCOS Long-Term Health Risks: From Infertility And Type 2 Diabetes To Heart Disease And Endometrial Cancer TheHealthSite
Published: Feb. 23, 2026, 1:56 p.m.
Endometrial cancer: AIFA approves immunotherapy with chemotherapy for all patients. - lamilano.it
Endometrial cancer: AIFA approves immunotherapy with chemotherapy for all patients. lamilano.it
Published: Feb. 23, 2026, 1:30 p.m.
Key Opinion Leader (KOL) Panel to Discuss Acrivon’s ACR-368 Endometrial Cancer (EC) Trial during the 2026 European Society of Gynecological Oncology (ESGO) Congress - The Manila Times
Key Opinion Leader (KOL) Panel to Discuss Acrivon’s ACR-368 Endometrial Cancer (EC) Trial during the 2026 European Society of Gynecological Oncology (ESGO) Congress The Manila Times
Published: Feb. 23, 2026, 1:16 p.m.
Link copied to clipboard!